Past Events ...

Tobin Dickerson, Ph.D.; Sep. 29, 2009
The Scripps Research Institute
"End-Game Strategies for Prediction and Detection of Evolving Disease"
Magid Abou-Gharbia, Ph.D.; Oct. 26, 2009
Temple University, School of Pharmacy
"Impact of Pharmaceutical Profiling and Natural Products Enabling Technologies on the
Discovery of Innovative Small Molecule Therapeutics"
Charles Reynolds, Ph.D.; Jan. 29, 2010
Ansaris Pharmaceuticals
Tutorial: "The Use of the Schrödinger Software Suite for Small Molecule Modeling and
Robert Raffa, Ph.D.; Mar. 25, 2010
Temple University, School of Medicine
"Planaria: A Model for Drug Action and Screen for CNS-active Therapeutics”
Greg Burdea, Ph.D.; May 13, 2010
Rutgers, The State University of New Jersey
"Avatars, Games and Clouds - The Future of Therapy, Today"
Donna Huryn, Ph.D.; May 20, 2010
University of Pennsylvania
"Using Chemistry to Answer Biological Questions: Small Molecule Probes of Tau, Hsp70,
and Cathepsins"
Eileen Jaffe, Ph.D.; Jun. 3, 2010
Fox Chase Cancer Center
"Morpheeins - A New Pathway for Drug Discovery"
Martin Pomper, M.D., Ph.D.; Jun. 10, 2010
Johns Hopkins Medical Institutions
"Translational Molecular Imaging"
Brendan Canning, Ph.D.; Jul. 10, 2010
Johns Hopkins Asthma and Allergy Center
"Cough: Novel Therapeutic Strategies for an Unmet Medical Need"
Erik Schwiebert, Ph.D.; Sep. 28, 2010
CEO, DiscoveryBioMed, Inc.
"Integrating Human Cell Physiology with Drug Design"
Chun-wa Chung, Ph.D.; Oct. 15, 2010
"Epigenetic Targets in Drug Discovery: Potent, Selective Inhibitors of BET Family
Bromodomains as Modulators of Histone Code Expression"

Bruce Molino, Ph.D., Peter Guzzo, Ph.D.; Feb. 24, 2011
AMRI (Albany Molecular)
"Discovery of Melanin Concentrating Hormone Receptor-1 (MCH1) Antagonists
for the Treatment of Obesity”
Scott Sieburth, Ph.D.; Mar. 17, 2011
Temple University
"Silicon as a Pharmaceutical Design Element”
Symposium: “Regulatory Requirements for IND Submission for Small Biotechnology Companies” May 9, 2011
Six speakers with industrial experience covered all aspects of this topic, with an emphasis on
case histories as examples of success and failure in preclinical development

* IND Development Plans to Enable First-in-Human Studies

   Pushpa Singh, Ph.D. and Mauricio Futran, Ph.D.

* Getting your Drug to Market - Drug Development 101

   Carol S. Auletta, M.B.A., D.A.B.T., R.A.C.

* Deciphering the CMC Regulatory Code: GCCGCTCMCFORTHEINDGCAGCG....

   Frederick (Simon) Golec, Jr., Ph.D.

* Drug Product: The Other Critical Part of Pre-Clinical Development

   Denita Winstead, Ph.D.

* Toxicology Considerations in Developing Biologics: A Case Study

   Robert M. Parker, Ph.D., D.A.B.T.

* IND-Enabling Study Requirements and Technical Considerations

   Aidan Curran, Ph.D.

Phil S. Baran, Ph.D.; Jul. 1, 2011
The Scripps Research Institute, La Jolla
"Studies in Natural Product Synthesis"

Geoffrey Dow, Ph.D.; Aug. 18, 2011
Walter Reed Army Institute of Research
“Next-Generation Cures for Malaria”

Bonnie Firestein, Ph.D.; Aug. 25, 2011
Rutgers, The State University
of New Jersey
“Dendrites: Branching from the Inside Out”

Stuart Palmer, Ph.D.; Sep. 22, 2011
BioConsulting International
"The Use of Standards and Controls in Real-Time PCR Diagnostic Applications”

First Annual PDDI Drug Discovery Award and Lecture
Dr. William J. Greenlee, of Merck Research Laboratories; Tuesday, 29 Nov. 2011
"Discovery of Drug Candidates for the Treatment of Parkinson's Disease and Alzheimer's Disease"

Workshop: “A Legal Primer for Scientists, Entrepreneurs and Biotech Companies." Mar. 29 2012
(in partnership with the Regional Biotech Council)
Dr. Joseph Aceto and a panel of experts. A round-table workshop to discuss legal issues in biotechnology. The workshop included senior legal experts in:
· Employment Law (employment & noncompete covenants, labor/management relations)
· International Trade Law (Chinese trade law, foreign joint ventures)
· FDA Law (drug and device development strategies, compliance)
· Patent and Trademark Law (securing an IP portfolio, branding)
· Commercial Transactions (commercial lending, mergers & acquisitions)
· General Corporate (corporate structure, shareholder agreements)
· Early stage finance (friends and family/seed stage/angel stage/venture capital finance)

Patrick Lam, Ph.D.; Apr. 5, 2012
"Structure-based Discovery of the Factor Xa Inhibitor, Eliquis® (Apixaban), a Novel Anticoagulant"

Scott Diamond, Ph.D.; Apr. 26, 2012
University of Pennsylvania
"High-Throughput Biotechnology"

George Trainor, Ph.D.; May 17, 2012
Trainor Consulting, LLC
"Chemical Principles of Drug Action In Vivo"

Lisa Minor, Ph.D.; Aug. 2, 2012
In Vitro Strategies, LLC
"Reproducible and Quantitative Analysis of Cell Morphology and Subcellular Structures through Controlling Cell Surface Adhesion-2D+"

Symposium at the American Chemical Society National Meeting in Phila.
The Pennsylvania Drug Discovery Institute (PDDI) sponsored a one-day symposium at the ACS National Meeting in Philadelphia, on Tuesday 21 Aug. 2012, in the Division of Small Chemical Businesses (Co-sponsors: ORGN, MEDI, COMP) on “Entrepreneurship: Drug Discovery Innovation at Startup and Medium-Sized Biotechnology Companies,” with Allen Reitz as Organizer and Chair.  Allen was also one of the speakers.  There were two 40-minute keynote lectures and 25-minute presentations.

Rodrigo Andrade, Ph.D.; Nov. 8, 2012
Temple University, Department of Chemistry
"Adventures in Chemical Synthesis--Part I: Discovery of Novel Macrolide Antibiotics; Part II: Total Synthesis of Strychnos Alkaloids"

Second Annual PDDI Drug Discovery Award and Lecture
Dr. John J. Baldwin, of Cleo Cosmetic and Pharmaceutical; Nov. 27, 2012
"The Decline in Industrial Drug Discovery and the Rise in Mergers, Alliances and Outsourcing"

James Hendrix, Ph.D.; Dec. 13, 2012
"Antipsychotics or Just Psychotic? - Adventures in CNS Drug Discovery"

Nicholas A. Meanwell, Ph.D.; Jan. 23, 2013
Bristol-Myers Squibb
"The Design and Discovery of Inhibitors of Hepatitis C Virus NS3 Protease and NS5A"

Daniela Zarnescu, Ph.D.; Jun. 13, 2013
University of Arizona
"Flies in Motion: What Can Drosophila Tell Us About ALS?"

Doron Greenbaum, Ph.D.; Jun. 27, 2013
University of Pennsylvania School of Medicine
"A Chemical Biology Approach to Understand Essential Proteins for Parasites"

James Arthos, Ph.D.; Aug. 22, 2013
National Institute of Allergies and Infectious Disease
"Glycosylation in HIV Transmission"

Mini-Symposium on “Entrepreneurship: Drug Discovery Innovation at Start-Up, Small and Medium-Sized Biotechnology Companies”; Sep. 26, 2013
 Patrick N. Confalone, Ph.D.: “Innovation and the Entrepreneur”
 Barbara S. Schilberg: “How to Think Like an Investor”
 Patrick M. Dentinger: “Entrepreneurism and the Future of Drug Development”

Third Annual PDDI Drug Discovery Award and Lecture
Dr. Jonathan Chernoff, Stanley P. Reimann Chair in Oncology at the Fox Chase Cancer Center, and Chief Scientific Officer/Senior Vice President of the FCCC; Dec. 3, 2013
"p21-Activated Kinases as Targets in Cancer Therapy"

Edward Zartler, Ph.D.; Jan. 30, 2014
Quantum Tessera Consulting
"Fragonomics: Practical Applications of Fragment-based Hit Generation"

Steven Sammut, MBA; Apr. 17, 2014
University of Pennsylvania, Wharton School of Business
“Gaining Ground: Biotechnology in the Developing World”

Tom Smithgall, Ph.D., Sep. 18, 2014
University of Pittsburgh, School of Medicine
"Coupling HIV Accessory Factors to Host Cell Kinases Enables HTS for Antiretroviral Drug Discovery"

Fourth Annual PDDI Drug Discovery Award and Lecture
Dr. Daniel M. Skovronsky, Senior Vice President of Product and Clinical Development at Eli Lilly & Co., and Founder/CEO of Avid Radiopharmaceuticals; Nov. 20, 2014
"My Drug Discovery Journey – from Pennsylvania Biotech to Big Pharma"

Ronald N. Harty, Ph.D.; May 14, 2015
University of Pennsylvania, School of Medicine
"Development of Host-Oriented Therapeutics Targeting Virus Egress"

Sridhar Mani, Ph.D.; May 28, 2015
Albert Einstein College of Medicine
“Development of PXR Antagonists for the Treatment of Liver Diseases”

Ronen Marmorstein, Ph.D.; Jun. 25, 2015
University of Pennsylvania, Perlman School of Medicine
"Structure-Guided Inhibitor Development in an Academic Setting"

Harold G. Selnick, Ph.D.; Sep. 17, 2015
Merck Research Laboratories (ret.)
"PGP Matters"

Fifth Annual PDDI Drug Discovery Award and Lecture
Prof. Amos B. Smith, III, University of Pennsylvania, Department of Chemistry; Nov. 19, 2015
“Current Synthetic, Bioorganic and Medicinal Research in the Smith Group”

Wen Li, Ph.D.; Feb. 29, 2016
NMS Labs, Inc.
“Synthetic Cannabinoids: Stay Current, Why and How?"

William Wuest, Ph.D.; Aug. 11, 2016
Temple University, Department of Chemistry
"Natural Product-Inspired Approaches to Combat Bacteria"

Sixth Annual PDDI Drug Discovery Award and Lecture
Prof. Eddy Arnold, Department of Chemistry & Chemical Biology, Rutgers University; Nov. 17, 2016
“Successful structure-guided design of anti-AIDS drugs with Dr. Paul Janssen and use of fragment screening to create new classes of antiviral agents targeting HIV and influenza.”

Seventh Annual PDDI Drug Discovery Award and Lecture
Dr. Joseph Tarnowski, Senior Vice President, Cell and Gene therapy Platforms, GlaxoSmithKline; Nov. 20, 2017
“Delivering Cell and Gene Therapy: One Big Pharma's Approach.”